Compare Gilead Sciences, Inc. (GILD) vs Lufax Holding Ltd (LU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Lufax Holding Ltd — how do they compare? Gilead Sciences, Inc. trades at $133.02 (market cap $163.51B), while Lufax Holding Ltd trades at $1.34 (market cap $2.41B). The key difference: Gilead Sciences, Inc. is far larger — about 67.8× Lufax Holding Ltd's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Lufax Holding Ltd pays none. Which is the better fit depends on your goals.
| GILD | LU | |
|---|---|---|
Market Cap | $163.51B | $2.41B |
Sector | Health | Technology |
52-Week High | $155.80 | $4.40 |
52-Week Low | $108.22 | $1.23 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
LU trades at $1.33, up 3.1% today, but technical indicators are bearish with moving averages signaling a downtrend. The company reported a net loss of $2.1 billion in 2025, with negative profit margins and returns. Multiple class-action lawsuits filed in May 2026 allege securities fraud, creating significant legal overhangs.
The outlook is challenged by persistent losses and legal risks, though low valuation ratios like P/S of 0.34 and P/B of 0.1 may attract value investors. Analyst consensus is moderately positive with 62% buy ratings, but investors face substantial downside risk from ongoing litigation and profitability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
